Get the Stockscreener App
0.628
2.18%
0.0235
Passage Bio Inc stock is traded at $0.628, with a volume of 89,898.
It is up +2.18% in the last 24 hours and down -4.82% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
See More
Previous Close:
$0.6045
Open:
$0.6
24h Volume:
89,898
Relative Volume:
0.31
Market Cap:
$38.23M
Revenue:
-
Net Income/Loss:
$-76.57M
P/E Ratio:
-0.3063
EPS:
-2.05
Net Cash Flow:
$-70.74M
1W Performance:
-3.06%
1M Performance:
-4.82%
6M Performance:
-52.85%
1Y Performance:
-5.84%
1-Day Range:
$0.60
$0.6457
1-Week Range:
$0.59
$0.6637
52-Week Range:
$0.54
$1.79
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
R. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, on Gene Therapy for APOE4 Homozygous Alzheimer Disease - CGTLive™
Layoff Tracker: Marinus Cuts Employees After Disappointing Phase III Trial - BioSpace
Passage Bio reports advances in gene therapy for dementia - Investing.com
Gene therapy shows promise in frontotemporal dementia study - Investing.com
Gene therapy shows promise in frontotemporal dementia study By Investing.com - Investing.com South Africa
Passage Bio reports advances in gene therapy for dementia By Investing.com - Investing.com South Africa
Passage Bio Presents Preclinical and Interim Clinical Data - GlobeNewswire
Will Passage Bio See An Uplift? Frontotemporal Dementia Trial Data Holds The Key - RTTNews
PASG stock touches 52-week low at $0.55 amid market challenges - Investing.com
Plexxikon, Inc. - Scrip
Passage Bio Inc [PASG] 10% Owner makes an insider purchase of 39,300 shares worth 27903.0. - Knox Daily
Director Mayson Howard John sale 4,000 shares of Ovintiv Inc [OVV] - Knox Daily
Passage Bio Inc (PASG) Stock: A Year of Highs and Lows - The InvestChronicle
Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision - MSN
Passage Bio stock hits 52-week low at $0.57 amid market challenges - Investing.com Australia
Jim Wilson’s new gene therapy company Gemma is getting up to $100M from Brazil - Head Topics
Daniela van Eickels, MD, PhD, MPH, on Bristol Myers Squibb’s Development of Cell Therapy for Autoimmune Disease - CGTLive™
Passage Bio stock hits 52-week low at $0.57 amid market challenges By Investing.com - Investing.com South Africa
Frontotemporal Dementia Pipeline 2024: Clinical Trials - openPR
Frontotemporal Dementia Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Alector, Oncolys BioPharma, Denali Therapeutics, Passage Bio - Barchart
Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment - MyChesCo
Passage Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MyChesCo
Passage Bio’s CEO to Present at Prestigious Genetic Medicines Conference - MSN
Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers - Yahoo Finance
Market Insights: Gatos Silver Inc (GATO)’s Notable Drop of -2.63, Closing at 15.18 - The Dwinnex
NanoMosaic Transforms Cell and Gene Therapy Analytics with Advanced Quantification and Genome Mapping Capabilities. World-Renowned Expert Dr. Guangping Gao to Join Nanomosaic Scientific Advisory Board - StreetInsider.com
OrbiMed Advisors sells shares in Passage BIO worth over $27k - Investing.com India
CASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above Two Hundred Day Moving Average of $4.60 - Defense World
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference - ForexTV.com
Mercer Global Advisors Inc. ADV Acquires 10,658 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MSN
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - Yahoo Finance
OrbiMed Advisors sells shares of Passage Bio worth over $146,000 - Investing.com
OrbiMed Advisors sells shares of Passage Bio worth over $146,000 By Investing.com - Investing.com UK
Canaccord sees Passage Bio stock potential in positive Phase 1/2 trial data - Investing.com
PASG’s 52-Week Rollercoaster: From $0.58 to $1.79 – What’s Next for Investors? - The InvestChronicle
Financial Metrics Unveiled: Passage Bio Inc (PASG)’s Key Ratios in the Spotlight - The Dwinnex
Passage Bio Reveals Promising Gene Therapy Trial Results - TipRanks
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) - StockTitan
Passage Bio to Present Positive Interim Data from Cohort 1 - GlobeNewswire
Cornercap Investment Counsel Inc. Has $5.64 Million Stake in Meta Platforms, Inc. (NASDAQ:META) - Defense World
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Passage Bio Inc Stock (PASG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Sep 17 '24 |
Sale |
0.73 |
111,400 |
81,322 |
7,859,500 |
| ORBIMED ADVISORS LLC | 10% Owner |
Sep 16 '24 |
Sale |
0.74 |
63,100 |
46,694 |
7,970,900 |
| ORBIMED ADVISORS LLC | 10% Owner |
Sep 18 '24 |
Sale |
0.73 |
25,631 |
18,711 |
7,833,869 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):